Plexium discloses preclinical evaluation of its selective IKZF2 molecular glue degrader
Sep. 2, 2024
Plexium Inc. has described the efforts that led to the discovery of PLX-4545, an orally bioavailable molecular glue degrader of IKZF2 for the treatment of cancer that is currently undergoing evaluation in a phase I study in healthy volunteers.